scispace - formally typeset
D

Dianne Alewood

Researcher at University of Queensland

Publications -  37
Citations -  2087

Dianne Alewood is an academic researcher from University of Queensland. The author has contributed to research in topics: Peptide & Amino acid. The author has an hindex of 20, co-authored 37 publications receiving 2045 citations. Previous affiliations of Dianne Alewood include Scripps Research Institute & Queensland University of Technology.

Papers
More filters
Journal ArticleDOI

In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences.

TL;DR: In this paper, simple, effective protocols have been developed for manual and machine-assisted Boc-chemistry solid phase peptide synthesis on polystyrene resins, which use in situ neutralization [i.e. neutralization simultaneous with coupling], high concentrations (> 0.2 M) of Bocamino acid-OBt esters plus base for rapid coupling, 100% TFA for rapid Boc group removal, and a single short (30 s) DMF flow wash between deprotection/coupling and between coupling/deprotection.
Journal ArticleDOI

In Situ Neutralization in Boc-chemistry Solid Phase Peptide Synthesis

TL;DR: The in situ neutralization protocols gave a significant increase in the efficiency of chain assembly, especially for “difficult” sequences arising from sequence-dependent peptide chain aggregation in standard (neutralization prior to coupling) Boc-chemistry SPPS protocols or in Fmoc- chemistry SPPS.
Book ChapterDOI

Rapid in situ neutralization protocols for Boc and Fmoc solid-phase chemistries

TL;DR: Together with modern analytical techniques for peptide analysis such as mass spectrometry (MS) and MS combined with liquid chromatography (LC–MS), it is now feasible to observe and determine the nature of the various side products in solid-phase peptide synthesis (SPPS).
Journal ArticleDOI

Anti-allodynic efficacy of the χ-conopeptide, Xen2174, in rats with neuropathic pain

TL;DR: Xen2174 appears to be a promising candidate for development as a novel therapeutic for i.t. administration to patients with persistent neuropathic pain, after confirming the noradrenergic mechanism of action.
Journal ArticleDOI

chi-Conopeptide pharmacophore development: toward a novel class of norepinephrine transporter inhibitor (Xen2174) for pain.

TL;DR: A pharmacophore model for the allosteric binding of 3 to NET is proposed and it is shown that 3 interacts with NET predominantly through amino acids in the first loop, forming a tight inverse turn presenting amino acids Tyr7, Lys8, and Leu9 in an orientation allowing for high affinity interaction with NET.